STAT+: FDA opens applications for new voucher program 

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We’ve got more developments with Sarepta today. My colleagues got exclusive comments from a senior FDA official — read on for what the official said.

The need-to-know this morning

• Roche is following its partner Sarepta Therapeutics and stopping shipments of the Duchenne muscular dystrophy gene therapy Elevidys in some countries, amid rising safety concerns surrounding the treatment.
• An experimental oral treatment from Abivax helped ease symptoms at compelling rates in patients with a type of bowel disease in a pair of Phase 3 trials. Shares of the Paris-based drugmaker are soaring this morning.

Sean Parker and ARCH launch a cancer biotech

A new biotech called Dispatch Bio launched today with the goal of developing a new, universal approach to try to treat any cancer using immunotherapy.

Continue to STAT+ to read the full story…